TCM
TXG icon

Tributary Capital Management’s 10x Genomics TXG Stock Holding History

Tributary Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,200
Closed -$1.07M – 228
2021
Q4 		$1.07M Buy
7,200
+1,500
+26% +$230K 0.08% 141
2021
Q3 		$830K Buy
+5,700
New +$979K 0.06% 155

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tributary Capital Management's TXG Position: Q1 2022 in Review

Tributary Capital Management sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 7,200 shares — an estimated $1.07M sold.

Tributary Capital Management first reported a position in TXG in Q3 2021 and held it in 2 quarters. The position peaked at $1.07M in Q4 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

  • Tributary Capital Management reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
  • Tributary Capital Management sold 7,200 10x Genomics shares in Q1 2022, an estimated $1.07M.
  • Tributary Capital Management first reported a position in 10x Genomics in Q3 2021 and held it in 2 quarters.
  • Tributary Capital Management's 10x Genomics position peaked at $1.07M in Q4 2021.
  • 314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Tributary Capital Management's 13F filing for Q1 2022, filed 22 Apr 2022.